Goldline Pharmaceutical Limited IPO: ₹8.35 Crore SME Fresh Issue Opens May 12, 2026

Goldline Pharmaceutical Limited, a Nagpur-based pharmaceutical marketing company incorporated in 2004, is set to launch its initial public offering (IPO) on May 12, 2026. The SME issue is a pure fresh issue of ₹8.35 crore with no offer for sale (OFS) component, and the IPO will close on May 14, 2026. The company markets pharmaceutical products under its proprietary 'Goldline' brand across five distinct segments, operating entirely on an asset-light, third-party contract manufacturing model with 15 contract manufacturers and 8 distributors.

IPO Structure and Key Dates

The offering details as disclosed in the Draft Red Herring Prospectus (DRHP) are summarised below.

Parameter: Details Issue Type: Fresh Issue Fresh Issue Size: ₹8.35 Crore Offer for Sale (OFS): Nil Total Issue Size: ₹8.35 Crore IPO Opening Date: 12-May-2026 IPO Closing Date: 14-May-2026 Allotment Date: 15-May-2026 Listing Date: 19-May-2026 Price Band: Not disclosed in DRHP

The net proceeds from the issue are intended for repayment of outstanding borrowings — including unsecured loans, term loans, and working capital facilities — with a portion allocated to general corporate purposes capped at the lower of 15% of gross proceeds or ₹1,000.00 lakhs.

Company Profile and Business Model

Goldline Pharmaceutical does not own or operate any manufacturing facility. Instead, it relies on 15 third-party contract manufacturers who produce products based on the company's market research, demand analysis, and specifications. Products are distributed through 8 distributors, with credit terms of 60 days extended to distributors. The company's geographic focus is concentrated in Maharashtra and Madhya Pradesh, which together account for over 70% of revenue.

The company markets products across five branded segments:

Goldline Pharma — Core pharmaceutical products

Goldline Cardinal — Specialty pharmaceutical range

Goldline Aayushman — Healthcare-focused products

Goldline InLife — Lifestyle and wellness products

Goldline Wellness — General wellness products

Three promoter group entities — Numerius Healthcare, Nucleage Lifescience, and Nucleage Pharma Solutions — are engaged in similar pharmaceutical businesses and collectively contributed 22.04% of the company's revenue as distributors, indicating significant related-party dependency.

Financial Performance

The company has reported consistent revenue growth over the reviewed periods. Revenue from operations grew from ₹19.85 crore in FY2023 to ₹23.57 crore in FY2024 and further to ₹28.06 crore in FY2025. For the nine months ended December 31, 2025 (Q3 FY2026), revenue stood at ₹21.41 crore.

Metric: FY2023 FY2024 FY2025 Q3 FY2026 (9M) Revenue from Operations (₹ Cr): 19.85 23.57 28.06 21.41 Revenue Growth (YoY): — +18.74% +19.05% N/A Total Expenses (₹ Cr): 19.45 21.04 24.20 18.40 PBT (₹ Cr): 0.40 2.52 3.86 3.01 PAT (₹ Cr): 0.26 1.80 2.83 2.22 PAT Margin (%): 1.31% 7.64% 10.09% 10.37% PBT Margin (%): 2.02% 10.69% 13.76% 14.06%

Profitability improved significantly over the period, with PAT margin expanding from 1.31% in FY2023 to 10.09% in FY2025. Total equity grew from ₹5.89 crore in FY2023 to ₹12.36 crore as of Q3 FY2026, while the debt-to-equity ratio declined from 2.29x to 1.22x over the same period. The current ratio improved from 1.87x in FY2023 to 2.24x in Q3 FY2026. Operating cash flows remained consistently positive across all periods reviewed.

Balance Sheet and Cash Flow Overview

The company's balance sheet reflects steady asset growth and improving equity position, as detailed below.

Metric: FY2023 (₹ Cr) FY2024 (₹ Cr) FY2025 (₹ Cr) Q3 FY2026 (₹ Cr) Total Assets: 19.39 22.93 26.28 27.40 Total Liabilities: 13.50 15.07 15.93 15.05 Total Equity: 5.89 7.86 10.35 12.36 Cash from Operations (₹ Cr): 2.39 2.92 2.32 2.32 Cash from Financing (₹ Cr): -1.44 -1.08 -2.03 -2.75 Net Cash Flow (₹ Cr): -0.09 0.74 0.45 -0.48

Total borrowings stood at ₹913.78 lakhs as of March 31, 2026. Trade receivables increased from ₹862.74 lakhs in FY2023 to ₹1,290.45 lakhs as of Q3 FY2026, reflecting the company's 60-day credit terms extended to distributors.

Key Risk Factors

Investors should note the following material risks disclosed in the DRHP:

Third-party manufacturer dependence: The company relies entirely on 15 contract manufacturers with lead times of 15–60 days, with no manufacturing backup.

Concentrated distribution: Only 8 distributors handle a significant portion of revenue, creating high counterparty concentration risk.

Related-party revenue dependency: Promoter group entities contributed 22.04% of revenue as distributors, alongside potential conflicts of interest given their engagement in similar businesses.

Geographic concentration: Maharashtra and Madhya Pradesh account for over 70% of revenue.

Outstanding litigation: Exposure includes ₹271.23 lakhs in direct tax matters, ₹63.70 lakhs in indirect tax matters, and ₹7.75 lakhs in regulatory actions.

Total borrowings: ₹913.78 lakhs as of March 31, 2026, with promoters as co-borrowers on unsecured loans totalling ₹1.67 crore.

Unrecognised MSME interest: Outstanding balances of ₹81.35 lakhs as of December 31, 2025, with an estimated interest liability of approximately ₹1.10 lakhs not yet provisioned.

Regulatory compliance lapses: Late fees totalling over ₹1.5 lakhs for ROC filing delays and late fees of ₹25,000+ for GST payment delays.

IPO proceeds allocation: The primary use of IPO proceeds is debt repayment rather than business expansion or capacity building.

Management Team

The promoters and key management personnel collectively bring more than 5 decades of combined industry experience in pharmaceutical marketing, distribution, and business development. The leadership team comprises the following individuals:

Name: Designation Amol Laxmikant Mujumdar: Managing Director (MD) Swapan Premprakash Khandelwal: Chief Executive Officer (CEO) Prashant Shrikrishna Karkare: Chief Operating Officer (COO) Avinash Pandurang Ambulkar: Chief Technology Officer (CTO) Prashant Vithalrao Rahate: Director Mehul Hari Ranade: Chief Financial Officer (CFO) Renuka Saurabh Borole: Vice President – Marketing Shraddha Kiran Kulkarni: Vice President – Sales

The price band, lot size, and reservation category details have not been disclosed in the DRHP data available. Investors are advised to refer to the complete DRHP and consult their financial advisors before making any investment decisions.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.